Loading...
•
Mar 31, 2025
Certara Q1 2025 Earnings Report
Reported financial results for the first quarter of fiscal year 2025
Key Takeaways
Certara reported strong first quarter 2025 results, with revenue increasing 10% year-over-year to $106.0 million. Both software and services segments contributed to growth. Net income significantly improved from a loss in the prior year period, and Adjusted EBITDA saw a substantial increase.
Total revenue for Q1 2025 was $106.0 million, a 10% increase from Q1 2024.
Software revenue grew by 18% to $46.4 million in Q1 2025.
Net income for Q1 2025 was $4.7 million, a significant improvement from a net loss of $4.7 million in Q1 2024.
Adjusted EBITDA increased by 20% to $34.8 million in Q1 2025.
Revenue by Segment
Forward Guidance
Certara is reiterating its full year 2025 financial guidance.
Positive Outlook
- Full year 2025 revenue is expected to be between $415 million and $425 million.
- Full year adjusted EBITDA margin is expected to be in the range of 30-32%.
- Full year adjusted diluted earnings per share is expected to be between $0.42 and $0.46.
- Fully diluted shares are expected to be in the range of 162 million to 164 million.
- Company is well positioned to support the continued adoption of Biosimulation.
Challenges Ahead
- Guidance reconciliation to GAAP measures is not provided due to variability and low visibility of certain costs.
- Variability of certain items could have an unpredictable and potentially significant impact on future GAAP results.
- Biopharma industry customers face challenges.
- Guidance is subject to risks and uncertainties outlined in forward-looking statements.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...